OrbiMed Advisors LLC, a leading investment management firm focused on the healthcare sector, is pleased to announce the closing of Caduceus Private Investments III, LP (CPI III), with $500 million in limited partner commitments. Consistent with OrbiMed's previous venture capital funds, CPI III will invest primarily in U.S. mid- and late-stage private life science companies engaged in the discovery and development of biopharmaceutical products or medical technologies (including medical devices, diagnostics, and discovery tools). The Fund will also invest opportunistically in public small capitalization biopharmaceutical and medical technology companies via privately negotiated transactions.
The fund is expected to be invested over a four to six year period with individual investments ranging from $12 million to $50 million.
OrbiMed is led by its five general partners: Samuel D. Isaly, Sven H. Borho, Carl L. Gordon, Michael B. Sheffery and Jonathan T. Silverstein. The private equity effort includes 8 dedicated professionals who draw on the resources and expertise of the entire 21 member team.
INFO SOURCES
OrbiMed Advisors LLC
FIRMS
OrbiMed is one of the world's largest fully-dedicated healthcare asset management firms, with over $6 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully made investments in over 70 companies across a wide range of therapeutic categories and stages of development. OrbiMed's investment team includes over 20 experienced professionals with backgrounds in science, medicine, finance and law. Our professionals work together using a collaborative, team-oriented approach which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages.
Supporting Material
